Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (TANGOKIDS)

  • End date
    Jun 17, 2023
  • participants needed
  • sponsor
    Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Updated on 26 January 2022
antibiotic therapy
renal function
absolute neutrophil count


A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections


In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of "last defense" for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many hospitals worldwide now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.

Rempex developed meropenem-vaborbactam administered as a fixed combination by IV infusion, to treat serious Gram-negative infections, such as cUTIs, including those infections caused by bacteria resistant to currently available carbapenems.

This study is an open label, dose-finding, pharmacokinetics, safety, and tolerability study of a single dose infusion of meropenem-vaborbactam in pediatric subjects from birth to less than 18 years of age with serious bacterial infections

Condition Bacterial Infections
Treatment Carbavance, Vabomere
Clinical Study IdentifierNCT02687906
SponsorRempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Last Modified on26 January 2022


Yes No Not Sure

Inclusion Criteria

A signed and dated written informed consent from the parent or legal representative and a subject assent (according to local IRB requirements)
Male or female from birth to < 18 years of age
Are hospitalized, in stable condition, and receiving systemic antibiotics for a known or suspected bacterial infection; or subjects receiving peri-operative prophylactic use of antibiotics
The subject will be observed in the hospital for at least 6 hours after the study drug is administered
If female and has reached menarche, or has reached Tanner Stage 3 breast development (even if not having reached menarche), the subject is practicing appropriate birth control or is sexually abstinent
Sufficient intravascular access (peripheral or central) to receive study drug
Subjects will be excluded from the study if any of the following exclusion
criteria apply prior to randomization
Signs of severe sepsis including
Shock or profound hypotension that is not responsive to fluid challenge
Hypothermia (core temperature < 35.6 C or 96.1 F)
Disseminated intravascular coagulation as evidenced by prothrombin time or partial thromboplastin time 2X the ULN or platelets < 50% of the lower limit of normal
Any surgical or medical condition which, in the opinion of the investigator, would put the subject at increased risk or is likely to interfere with study procedures or PK of the study drug
Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant) during the entire study period
Female adolescent subjects who are pregnant or breastfeeding or have a positive serum -hCG pregnancy test at screening and at pre-dose Day 1
Males who are unwilling to practice abstinence or use an acceptable method of broth control during the entire study period (i.e. condom with spermicide)
Renal function at screening as estimated by creatinine clearance < 50 mL/min using the Cockcroft-Gault formula
Treatment within 30 days prior to enrollment with valproic acid
Treatment within 30 days prior to enrollment with probenecid
Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy
Neutropenia with absolute neutrophil count (ANC) < 500 cells/mm3
Aspartate aminotransferase or alanine aminotransferase 3X ULN or total bilirubin 1.5X ULN
Receipt of any investigational medication or investigational device within 30 days prior to enrollment
Prior exposure to vaborbactam or Vabomere
Use of meropenem within 48 hours of administration of study drug or 12 hours after study drug administration
Known significant hypersensitivity to any beta-lactam antibiotic
Unable or unwilling in the judgment of the Investigator, to comply with the protocol
An employee of the Investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member of the employee or the Investigator
BMI outside the range (below the 5th percentile or above the 95th percentile) for height, age and weight except for children < 2 years of age.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note